Carrick Therapeutics believes in developing novel molecules to create better lives for patients. We are working on best-in-class and first-in-class therapies to complement existing treatments for several aggressive and resistant cancer types.
Our lead program, samuraciclib, is a cyclin dependent kinase 7 (CDK7) inhibitor. The CDK7 target is implicated in many cancers, including breast, prostate and pancreatic cancer.
View our CDK7 inhibitor
We are developing a therapy that uses a molecule which is a dual Cyclin dependent kinase 12/13 (CDK12/13) inhibitor and Cyclin-K degrader. CDK12/13 is implicated in multiple cancer types including breast, ovarian and Ewing's Sarcoma.
View our CDK12/13 inhibitor/Cyclin-K degrader